

Appropriate targeting of artemisinin-based combination therapy by community health workers using malaria rapid diagnostic tests: findings from randomized trials in two contrasting areas of high and low malaria transmission in south-western Uganda

Richard Ndyomugenyi¹, Pascal Magnussen², Sham Lal³, Kristian Hansen⁴ and Siân E. Clarke³

¹ Vector Control Division, Ministry of Health, Kampala, Uganda

² Centre for Medical Parasitology, Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

³ Department of Disease Control, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK

⁴ Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK

Abstract

OBJECTIVE To compare the impact of malaria rapid diagnostic tests (mRDTs), used by community health workers (CHWs), on the proportion of children <5 years of age receiving appropriately targeted treatment with artemisinin-based combination therapy (ACT), vs. presumptive treatment.

METHODS Cluster-randomized trials were conducted in two contrasting areas of moderate-to-high and low malaria transmission in rural Uganda. Each trial examined the effectiveness of mRDTs in the management of malaria and targeting of ACTs by CHWs comparing two diagnostic approaches: (i) presumptive clinical diagnosis of malaria [control arm] and (ii) confirmatory diagnosis with mRDTs followed by ACT treatment for positive patients [intervention arm], with village as the unit of randomisation. Treatment decisions by CHWs were validated by microscopy on a reference blood slide collected at the time of consultation, to compare the proportion of children <5 years receiving appropriately targeted ACT treatment, defined as patients with microscopically-confirmed presence of parasites in a peripheral blood smear receiving artemether-lumefantrine or rectal artesunate, and patients with no malaria parasites not given ACT.

RESULTS In the moderate-to-high transmission area, ACT treatment was appropriately targeted in 79.3% (520/656) of children seen by CHWs using mRDTs to diagnose malaria, vs. 30.8% (215/699) of children seen by CHWs using presumptive diagnosis ($P < 0.001$). In the low transmission area, 90.1% (363/403) children seen by CHWs using mRDTs received appropriately targeted ACT treatment vs. 7.8% (64/817) seen by CHWs using presumptive diagnosis ($P < 0.001$). Low mRDT sensitivity in children with low-density parasitaemia (<200 parasites/ μ l) was identified as a potential concern.

CONCLUSION When equipped with mRDTs, ACT treatments delivered by CHWs are more accurately targeted to children with malaria parasites. mRDT use could play an important role in reducing overdiagnosis of malaria and improving fever case management within iCCM, in both moderate-to-high and low transmission areas. Nonetheless, missed treatments due to the low sensitivity of current mRDTs in patients with low parasite density are a concern. For community-based treatment in areas of low transmission and/or non-immune populations, presumptive treatment of all fevers as malaria may be advisable, until more sensitive diagnostic assays, suitable for routine use by CHWs in remote settings, become available.

keywords Rapid diagnostic test (RDT), artemisinin-based combination therapy (ACT), community health workers (CHWs), appropriately targeted treatment, Uganda, community case management

Introduction

Early diagnosis and effective case management is a central component of the current malaria control strategy [1, 2], yet millions live at or beyond the periphery of the health system. Improving access to care for childhood infectious diseases by bringing treatment closer to the community is an attractive option, especially in rural settings where distance, cost and infrastructural challenges of primary healthcare centres limit access to expert services [3]. Targeting artemisinin-based combination therapy (ACT) to those who are parasitologically confirmed malaria cases is critical in reducing misdiagnosis and overuse of these expensive drugs and may play an important role in the financial sustainability of community-based programmes [4–6]. The World Health Organization (WHO) now recommends universal access to malaria diagnostics [7], and at the moment, antigen-based rapid diagnostic tests (mRDTs) are the only feasible test at community level. The case for their use rather than presumptive treatment is strong, due to lack of accurate algorithm-based diagnosis [8] and negative consequences of overuse of antimalarials [6]. Although there is evidence that mRDTs and ACTs can be successfully deployed at community level [9, 10], there is little information on whether their use improves the targeting of ACTs to malaria patients at that level, especially in low transmission settings. We conducted a cluster-randomized controlled trial to compare the impact of mRDTs, used by CHWs, on the proportion of children <5 years of age receiving appropriately targeted treatment with ACT, *vs.* presumptive treatment. The study took place in two different malaria transmission settings in rural Uganda to provide evidence to optimise use of ACTs and mRDTs within programmes of integrated community case management (iCCM) that are currently being scaled up in Uganda and other countries.

Materials and methods

Study area

The study was conducted in Rukungiri District, south-western Uganda, inhabited by the Bahororo and Bakiga ethnic groups, whose main occupation is subsistence farming. Anaemia among under-fives in south-western Uganda is estimated at 40%, and in other regions of the country, it ranges from 57% to 74% [11]. The district was selected for the study due to its wide altitudinal range between 980 and 2160 m above sea level, resulting in diverse malaria transmission patterns within the same district. Two subcounties with contrasting malaria transmission were selected as trial sites: Bwambara subcounty,

a lower altitudinal area bordered by Lake Edward, which is meso-endemic for malaria with moderate-to-high transmission, and Nyakishenyi subcounty, an epidemic-prone highland area with low transmission, which is hypo-endemic for malaria.

All villages in the two subcounties were invited to participate in the trial: 63 villages in Bwambara, ranging between 981–1203 m, and 64 villages in Nyakishenyi, ranging between 1064–2157 m. A public meeting was held in each eligible community to explain the purpose of the research, and community members were asked to identify 2–3 CHWs per village for training. Written informed consent to take part in the trial was sought from community leaders and all CHWs selected for training, of whom more than 50% had previously worked in the home-based management of fever (HBMF) programme that was defunct at the time of the study.

Trial design

A cluster-randomized two-arm trial design was used to compare the effectiveness of mRDTs used by CHWs to diagnose and treat malaria with ACT [intervention] to presumptive diagnosis and treatment of malaria with ACT [control]. The unit of randomisation was the village, with all CHWs in the same village receiving the same type of training. Within each transmission area (subcounty), villages were randomly allocated, using a random number table in Epi Info, to either the intervention (mRDT) or control (presumptive treatment) arm.

Community health workers in both arms of the trial were trained in recognising signs and symptoms of malaria, how to administer antimalarial treatment and when to refer (Figure 1, Table 1). Half of the villages were randomized to receive additional training in malaria diagnosis using mRDTs (intervention villages) and trained to only give antimalarial treatment with ACT after a positive test result, with the aim to increase the proportion of children receiving appropriately targeted treatment.

Intervention

Participatory training workshops in malaria case management were held for CHWs in each arm, based on a trainer's manual and accompanying set of pictorial job aids (available from www.actconsortium.org/RDThomemanagement). Training workshops lasted 3 days for CHWs in the control arm and 4 days for CHWs in the mRDT intervention arm. The latter received an additional 1-day training to cover the rationale for diagnostic testing in febrile patients, performing an mRDT and interpretation




Figure 1 Design of an intervention to support use of malaria diagnostic tests (mRDTs) by community health workers in Uganda.

Table 1 Training and supporting interventions for community health workers in the intervention and control arms

	Control arm	Intervention arm
3- to 4-day training workshop		
Reasons for policy change to mRDT testing before malaria treatment		✓
How to perform and interpret a mRDT		✓
What to do for patients with a negative mRDT result		✓
How to treat a child with malaria	✓	✓
How to recognise and treat a child with signs of severe illness, and when to refer	✓	✓
How to recognise a child with fevers caused by other illnesses, and when to refer	✓	✓
Role-play and communication skills	✓	✓
Supporting interventions for trained CHWs		
Training certificate with Ministry of Health logo	✓	✓
ACTs: age-appropriate pre-packed blister packs with pictorial labelling	✓	✓
Pictorial job aids	✓	✓
Close support supervision after training – for first 6 months only	✓	✓
Bicycle, T-shirt, monthly kerosene allowance and soap	✓	✓
Supporting interventions in the community		
Community-directed selection of CHWs by popular vote	✓	✓
Community sensitisation about mRDTs (community meetings, churches, women's groups)	✓	✓

of the test result based on training materials from WHO [12]. CHWs in the intervention arm were trained to treat children with a mRDT-positive test and symptoms of uncomplicated malaria with artemether–lumefantrine; and to treat mRDT-positive children with danger signs with rectal artesunate as a pre-referral treatment, and refer these children to the nearest health unit. CHWs were also trained to refer mRDT-negative children if the child either had danger signs or other specific symptoms where examination and treatment at a health facility would be beneficial.

Community health workers in the control villages were trained to either dispense artemether–

lumefantrine or rectal artesunate based on presumptive diagnosis of malaria, according to signs and symptoms. The training, support materials and procedures were identical in every respect except for the method of diagnosis to be used. In both arms, CHWs were trained in signs for referral (Box 1), completion of treatment records, stock management and preparation of blood slides for reference microscopy. Training encouraged interactive discussion and reflective practice, supported by role-play to practice communication skills necessary to obtain clinical history and explain outcome of diagnosis, treatment given and referral advice.

Box 1 Referral guidelines for community health workers

(a) Danger signs for urgent referral

Refer using emergency referral form if child shows any of the following symptoms:

- 1 Convulsions or fits now or within the past 2 days
- 2 Coma/loss of consciousness
- 3 Patient is confused or very sleepy; cannot be woken
- 4 Extreme weakness – unable to stand or sit without support
- 5 Very Hot – with temperature of 38.5°C or more
- 6 Very Cold – with temperature of 35.0°C or less
- 7 Vomiting everything – cannot keep down food or drink
- 8 Not able to drink or breastfeed
- 9 Severe anaemia – very pale palms, fingernails, eyelids
- 10 Yellow eyes
- 11 Difficulty in breathing
- 12 Severe dehydration – sunken eyes, sunken fontanelle, skin pinch, coated tongue

If RDT result is positive

Treat child (if older than 2 months) with rectal artesunate suppository prior to referral.

(b) Other signs for referral

Refer using ordinary referral form if child shows any of the following symptoms:

- 1 Fever that has lasted for more than 7 days
- 2 Fever with measured temperature of 37°C or more and a negative malaria test result
- 3 Vomiting and diarrhoea
- 4 Blood in faeces or blood in urine
- 5 Pain when passing urine, or frequent urination
- 6 Wound or burns
- 7 Skin abscess
- 8 Painful swelling or lumps in the skin
- 9 Ear infection (runny ear or child pulling at ear)
- 10 Sticky or red eyes
- 11 Fever in a baby <4 months old

If RDT result is positive

Treat child (if older than 4 months) with artemether–lumefantrine tablets prior to referral.

Supporting interventions

Recognising that CHWs may need to broker the change in diagnostic practice with communities, the training included practice in communication skills necessary to explain the rationale for diagnostic testing, result of the mRDT test and treatments given. In addition, community sensitisation on diagnostic testing for malaria was carried out throughout the study area prior to the trial (including communities in both arms). The key messages were that not all fevers are malaria and hence a diagnostic test was advisable before treatment with ACT; and a quick test (mRDT) could test for malaria, and these tests were available from government health facilities and trained CHWs in the intervention villages.

For the first 6 months of implementation (July–December 2010), CHWs in both arms received additional close support supervision by project staff through parish-level CHW meetings to assist adoption of the new procedures into everyday practice, to promote accurate and complete record keeping and to give advice on how to handle difficult situations that could affect adherence, for example caretakers insisting on treatment even after a negative RDT result. At the end of the 6 months, supervision was scaled back to periodic contacts when CHWs came to collect their supplies and a monthly allowance for paraffin and soap intended to support good hygiene and work in the evening/night (15 000 Uganda Shilling, approximately 4.50 USD). CHWs were also provided with pictorial job aids,

training certificates, bicycles and T-shirts at the start of the programme. Although CHWs in Uganda are volunteers, expected to work for free, programmes often provide small ‘refunds’ or tokens, which are generally expected as compensation.

Evaluation of outcomes

Data on diagnosis and treatment were recorded prospectively on all children seeking treatment for fever in carbon-copy duplicated CHWs’ registers, provided for this purpose. The treatment register for CHWs in the control arm was similar to the intervention arm except for data on mRDT result. CHWs in both arms were trained on how to prepare a thick blood film for every child with fever who consulted them, for later microscopy, subject to verbal assent given by the caretaker accompanying the child. Treatment decisions made by CHWs were validated by light microscopy on the reference blood slide collected at the time of consultation, to compare appropriate targeting of ACTs between arms over a 12-month period (January–December 2011). The primary endpoint was the proportion of febrile children with malaria receiving appropriately targeted treatment with a first-line antimalarial, a composite outcome defined as: children with microscopically-confirmed presence of parasites in a peripheral blood smear (slide positive) who received either artemether–lumefantrine or rectal artesunate, and febrile children with no malaria parasites (slide negative) who did not receive either of these two

artemisin-based treatments (denominator: all consultations for fever or history of fever). The other co-primary outcome was prompt effective treatment defined as the proportion of febrile children who received appropriately targeted ACT treatment from a CHW within 24 h of onset of malaria symptoms, while the secondary outcome was over-prescription defined as the proportion of children not parasite-positive (slide negative) who received inappropriate ACT treatment from CHW (denominator: all children with a negative research slide).

Sample size estimation

Based on an observed prevalence of malaria of 50% and inter-cluster variation $k = 0.35$ in the moderate-to-high transmission area during the period of close support supervision, a minimum sample size of 6 patients per cluster (180 patients per arm) was required to demonstrate a 50% increase in appropriately targeted treatment with use of mRDTs from 50% to 75%, with 90% power at the 5% significance level, in a cluster-randomised trial with 30 clusters per arm. The equivalent sample size in the low transmission area, with 30% malaria prevalence, 32 clusters per arm and inter-cluster variation $k = 0.45$, to demonstrate an increase from 30% to 65% was 2 patients per cluster (128 patients per arm). Taking into account the lower proportion of cases seeking treatment within 24 h of onset of symptoms (89% and 83% in each site), sample size requirements to detect a comparable increase in prompt appropriately targeted treatment were 9 patients and 3 patients per cluster (270 and 192 per arm), in the high-to-moderate and low transmission areas respectively.

Laboratory methods

A finger-prick blood sample was collected by the CHW at the time of consultation, a thick blood film for microscopy prepared, and mRDT (First Response[®] Ag. *P. falciparum* (HRP2) Card test, www.PremierMedCorp.com; intervention arm only) performed. The mRDTs passed independent quality-assurance batch testing by WHO-FIND, Institut Pasteur, Cambodia. Thick blood smears were haemolysed and stained with 10% Giemsa for 10 min and examined under light microscopy with oil immersion objective lens ($\times 100$). Asexual parasites were counted against 200 white blood cells and parasite densities calculated assuming a standard white blood cell count of 8000/ μ l blood. A blood smear was declared negative if no parasites were detected in 100 high power fields. Reference slides included in the analysis of the primary endpoint were subjected to two independent readings by light microscopy. The second reading was

performed by experienced technicians at Vector Control Division, Ministry of Health in Kampala, blinded to initial results. Any discrepant results between the first and second readings were resolved by a third technician blinded to all previous results. As the number of consultations in Bwambara (moderate-to-high transmission area) exceeded the sample size requirements, a subsample of blood slides was randomly selected for analysis of the primary endpoint. To reflect seasonal variation in the prevalence of malaria, two slides were randomly sampled per month from each village during the main evaluation period from January to December 2011 for double reading (a total of 24 slides per cluster). Malaria was less common in Nyakashenyi, with fewer consultations, and thus, all available slides were re-examined by expert microscopy.

Statistical methods

Data were analysed as intention-to-treat, with analysis conducted separately for each transmission setting. Due to the withdrawal of some clusters from the study after randomisation in the moderate-to-high transmission setting (Figure 2), data were analysed as modified-intention-to-treat. To account for cluster-randomised design, a random effects logistic regression model was used to estimate intervention effects and 95% confidence intervals; a quadrature check performed to confirm model was a reliable fit to the data, and likelihood ratio test used to assess statistical significance [13]. The analytical plan was approved by an independent data safety and monitoring board, prior to analysis. Data were double-entered and verified using Microsoft Access 2007 (Microsoft Inc., Redmond, USA) and analysed using STATA version 12 (STATA Corporation, College Station, Texas, USA).

Ethical approval

This study was approved by the Uganda National Council for Science and Technology and the London School of Hygiene & Tropical Medicine Ethics Committee. Patients refusing an mRDT test received presumptive treatment. The study was registered with ClinicalTrials.gov. Identifier NCT01048801 on 13 January 2010.

Results

To account for seasonal variations in malaria risk, data were analysed for a 12-month period of routine implementation (January–December 2011), after the training and 6-month period of close support supervision had ended. During 2011, a total of 13 035 children were seen by




Figure 2 Trial profile, moderate-to-high transmission area.

¹After training, CHWs in villages located close to the border of the study area started to receive febrile children from outside the study district; these villages were subsequently withdrawn from the trial.




Figure 3 Trial profile, low transmission area.



(a) Bwambara sub-county, moderate-to-high malaria transmission setting**(b) Nyakishenyi sub-county, low transmission setting**

Figure 4 Consultations for fever, malaria blood slide and rapid diagnostic test positivity by month in two areas of contrasting malaria transmission intensity in south-western Uganda: January–December 2011. (a) Bwambara subcounty, moderate-to-high transmission setting. (b) Nyakishenyi subcounty, low transmission setting.

CHWs in 63 villages in Bwambara subcounty (the moderate-to-high malaria transmission area), with 5715 children seen by CHWs in the mRDT intervention arm and 7320 in the control arm (Figure 2). In Nyakashenyi subcounty (the low transmission area), a total of 2676 children were registered by CHWs in 64 villages during the same period: 908 and 1768 in mRDT and presumptive arm, respectively (Figure 3). Most patients were willing to provide a blood sample, in all study arms, with few refusals.

In both transmission settings, the number of consultations in the control arm usually exceeded those in the mRDT arm, although the seasonal pattern was similar across arms (Figure 4). In Bwambara subcounty, changes in mRDT positivity mirrored changes in blood slide positivity. In Nyakashenyi subcounty, slide positivity was generally <10%, but increased to 35.7% in August 2011;

mRDT positivity reached a peak of 9% in the same month.

Effect of intervention on appropriately targeted treatment: moderate-to-high transmission setting

Of the 12 914 blood slides collected by CHWs in Bwambara subcounty, 1543 were sampled for validation of the treatment decision by expert microscopy (Figure 2). Appropriately targeted treatment was evaluated in patients for whom data on two or more independent slide readings were available: 699 patients in the control arm and 656 patients in the mRDT intervention arm, comprising 87.0% and 88.6% of the slides sampled in each arm, respectively. CHW and patient characteristics were generally similar between the two arms (Table 2).

Table 2 Characteristics of clusters and community health workers in the intervention and control arms

	Moderate-to-high transmission		Low transmission	
	Control arm Frequency (%)	Intervention arm Frequency (%)	Control arm Frequency (%)	Intervention arm Frequency (%)
Number of participating villages	31	32	32	32
Total number of CHWs	90	90	96	96
CHWs characteristics*				
Total CHWs interviewed	74	81	21	17
Age in years	Median	39	40	41
Sex	Male	24 (32.4)	26 (32.1)	6 (28.6)
	Female	50 (67.6)	55 (67.9)	15 (71.4)
Highest level of school attendance	Never	1 (1.6)	6 (6.4)	0 (0)
	Primary	40 (64.5)	46 (59.0)	11 (52.4)
	Secondary	20 (33.9)	21 (33.3)	10 (47.6)
	Tertiary	0 (0)	1 (1.3)	0 (0)
CHW before	Yes	47 (65.3)	39 (52.7)	14 (66.7)
	No	25 (34.7)	35 (47.3)	7 (33.3)
Involvement in health activities before	Yes	21 (30.0)	31 (45.6)	5 (26.3)
	No	49 (68.1)	37 (50.0)	14 (66.7)
Elevation (metres above sea level)	Mean (SD)	1131.21 (184.9)	1086.0 (53.7)	1829.8 (110.0)
Patient characteristics†				
Total number of children seen by CHW		699	656	817
Age in years	Mean (SD)	2.8 (1.5)	2.6 (1.4)	2.6 (1.4)
Sex	Male	359 (51.7)	335 (51.1)	434 (53.2)
	Female	336 (48.3)	320 (48.9)	382 (46.8)
Slept under a mosquito net the previous night	Yes	639 (92.7)	567 (87.4)	737 (91.1)
	No	50 (7.3)	82 (12.6)	72 (8.9)
Resident in same village as CHW	Yes	644 (92.5)	599 (91.6)	732 (89.8)
	No	52 (7.5)	55 (8.4)	83 (10.2)
Time of presentation to CHW after of onset of symptoms	Within 24 h	641 (93.4)	544 (84.6)	698 (88.8)
	More than 24 h	45 (6.6)	99 (15.4)	88 (11.2)

*Data missing in moderate-to-high transmission setting, for highest level of school attendance: 21 (13 control, 8 intervention); previous CHW status: 9 (2 control arm, 7 intervention); involvement in health activities before: 17 (4 control, 13 intervention). Data missing in low transmission setting, for involvement in health activities before: 3 (2 control, 1 intervention).

†Data missing in moderate-to-high transmission setting, for age: 4 (2 control, 2 intervention); sex: 5 (4 control, 1 intervention); net use: 17 (10 control, 7 intervention); resident in same village 5 (3 control, 2 intervention); onset of symptoms: 26 (13 control, 13 intervention). Data missing in low transmission setting, for age: 14 (5 control, 9 intervention); sex: 2 (1 control, 1 intervention); net use: 11 (8 control, 3 intervention); resident in same village: 4 (2 control, 2 intervention); onset of symptoms: 36 (31 control, 5 intervention).

While over 80% of patients had sought treatment within 24 h of onset of symptoms, there was greater delay in the mRDT intervention villages than controls. Slide positivity was also higher in the mRDT intervention arm, 37.8% *vs.* 30.2% control (Table 3), with 37.6% of children in the intervention arm testing mRDT positive. The sensitivity and specificity of mRDT result against expert microscopy were 72.1% and 83.3%, respectively, with a positive predictive value (PPV) of 72.4% and negative predictive value (NPV) of 83.1% in this area of moderate-to-high transmission (Table 5).

Among febrile children seen by CHWs in the mRDT intervention arm, 37.5% were treated with either artemether–lumefantrine or rectal artesunate (hereafter referred to collectively as ACT) compared with almost 100% of children seen by CHWs using presumptive diagnosis (Table 3). Only 16.4% of slide-negative children in the mRDT intervention arm received an ACT, a significant reduction in over-prescription compared with the control arm, $P < 0.001$. Sixty-nine of the patients in the mRDT intervention arm who did not receive ACT treatment were slide positive, of whom 35 (51%) had parasite densities ≤ 200 parasites per μl (Figure 5a). Use of

Table 3 Diagnosis and treatment of malaria by CHWs in Bwambara subcounty, January–December 2011: moderate-to-high transmission setting

Diagnosis and treatment	Control arm 31 clusters Frequency (%)	Intervention arm 32 clusters Frequency (%)		
Patients with complete data for primary endpoint	699	656		
Blood slide positive	211 (30.2)	248 (37.8)		
mRDT positive*	n/a	243 (37.6)		
Malaria treatment prescribed				
Artemether-lumefantrine tablets (AL)	692 (99.0)	244 (37.2)		
Rectal artesunate suppository	3 (0.4)	2 (0.3)		
Neither AL nor rectal artesunate	4 (0.6)	410 (62.5)		
Malaria treatment by infection status				
Blood slide negative, received no ACT†	4 (0.8)	341 (83.4)		
Blood slide negative, received ACT	484 (99.2)	67 (16.4)		
Blood slide positive, received ACT	211 (100.0)	179 (72.2)		
Blood slide positive, received no ACT	0 (0.0)	69 (27.8)		
Trial endpoints	<i>n</i> (%)	<i>n</i> (%)	Odds ratio (95% CI)	<i>P</i>-value
Over-prescription				
Proportion of blood slide negative patients receiving ACT†	484 (99.2)	67 (16.4)	0.0013 (0.0004–0.0039)	<0.001
Appropriately targeted treatment				
Proportion of febrile patients receiving appropriately targeted malaria treatment with ACT	215 (30.8)	520 (79.3)	9.71 (6.83–13.80)	<0.001
Prompt and appropriately targeted treatment				
Proportion of febrile patients receiving appropriately targeted treatment within 24 hours of onset of symptoms‡	195 (28.1)	433 (67.0)	5.92 (4.15–8.45)	<0.001

*Ten patients missing RDT results.

†ACT defined as receiving either artemether-lumefantrine or rectal artesunate.

‡Fifteen missing data on time of treatment (five control, 10 intervention).

mRDTs was thus associated with a significant overall improvement in the targeting of ACT treatments, such that in this area of moderate-to-high transmission, 79.3% of children in the mRDT arm received appropriately targeted treatment compared with 30.8% in the control arm (odds ratio 9.71, 95% CI 6.83–13.80; $P < 0.001$).

Despite greater delay in seeking treatment in the mRDT arm, the proportion of children who received appropriately targeted treatment within 24 h was also significantly higher in the intervention arm (67.0% *vs.* 28.1%; odds ratio 5.92, 95% CI 4.15–8.45; $P < 0.001$).

Effect of intervention on appropriately targeted treatment: low transmission setting

A total of 2543 blood slides were collected by CHWs in Nyakashenyi subcounty, of which two or more independent slide readings were available for 49.0% and 47.1% of slides in the control and mRDT arm, respectively

(Figure 3). Patient records missing treatment data were few. Appropriately targeted treatment was thus evaluated in the 817 and 403 patients with complete data in the control and mRDT intervention arms, comprising 46.2% and 44.4% of consultations in each arm, respectively. Reasons for data loss included poor quality of the slides prepared by CHWs and missing data on validation microscopy. CHW and patient characteristics were similar between the two arms, although, as in the high transmission area, there was slightly greater treatment delay in mRDT intervention villages than controls; 80.2% *vs.* 88.8%, respectively, had sought treatment within 24 h of onset of symptoms (Table 2). Slide positivity was 5.7% overall, and similar in the two arms (Table 4), with 3.0% of children in the intervention arm reported to be mRDT positive. The sensitivity of mRDT result against microscopy was low (20.8%), and specificity was 98.1% (Table 5). PPV in this low transmission setting was 41.7%, and NPV, 95.1%.

Table 4 Diagnosis and treatment of malaria by CHWs in Nyakishenyi subcounty, January–December 2011: low transmission setting

Diagnosis and treatment	Control arm	Intervention arm		
	32 clusters Frequency (%)	32 clusters Frequency (%)	Odds ratio (95% CI)	P-value
Patients with complete data for primary endpoint	817	403		
Blood slide positive	46 (5.6)	24 (6.0)		
mRDT Positive*	n/a	12 (3.0)		
Malaria treatment prescribed				
Artemether-lumefantrine tablets (AL)	773 (94.6)	22 (5.5)		
Rectal artesunate suppository	18 (2.2)	6 (1.5)		
Neither AL nor rectal artesunate	26 (3.2)	375 (93.1)		
Malaria treatment by infection status				
Blood slide negative, received no ACT†	22 (2.9)	357 (94.2)		
Blood slide negative, received ACT	749 (97.2)	22 (5.8)		
Blood slide positive, received ACT	42 (91.3)	6 (25.0)		
Blood slide positive, received no ACT	4 (8.7)	18 (75.0)		
Trial endpoints	n (%)	n (%)		
Over-prescription				
Proportion of blood slide negative patients receiving ACT	749 (97.2)	22 (5.8)	0.00022 (0.00004–0.00125)	0.002
Appropriately targeted treatment				
Proportion of febrile patients receiving appropriately targeted malaria treatment with ACT	64 (7.8)	363 (90.1)	162.9 (83.0 – 319.6)	<0.001
Prompt and appropriately targeted treatment				
Proportion of febrile patients receiving appropriately targeted treatment within 24 hours of onset of symptoms‡	49 (6.0)	287 (72.1)	40.3 (28.1 - 57.9)	<0.001

*One patient missing mRDT result.

†ACT defined as receiving either artemether-lumefantrine or rectal artesunate.

‡Nine missing data on time of treatment (four control, five intervention).

Table 5 Sensitivity and specificity of malaria rapid diagnostic tests (mRDTs) performed by community health workers in two areas of contrasting transmission intensity

Result reported by CHW*	Moderate-to-high transmission setting			Low transmission setting		
	Expert microscopy†		Predictive value of mRDT, %	Expert microscopy†		Predictive value of mRDT, %
	Positive (%)	Negative (%)		Positive (%)	Negative (%)	
mRDT positive	176 (72.1)	67 (16.7)	72.4	5 (20.8)	7 (1.9)	41.7
mRDT negative	68 (27.9)	335 (88.3)	83.1	19 (79.2)	371 (98.1)	95.1
Total samples examined	244	402		24	378	

*Missing data on RDT result: 10 in high transmission setting; 1 in low transmission setting.

†Result of blood slides double-read by two independent microscopists, with discrepant findings resolved by a third independent reader; all blind to RDT result.

When compared with malaria status by microscopy, 5.8% of slide-negative children in the mRDT intervention arm received an ACT, a significant reduction in overprescription compared with control arm, $P = 0.002$

(Table 4). However, of the 24 patients who were slide positive, only 6 had received ACT treatment; 17 of the 18 that were untreated had parasite densities ≤ 200 parasites per μl (Figure 5b). Overall, use of mRDTs was




Figure 5 Rapid diagnostic test results performed and read by community health workers in relation to parasite density measured by expert light microscopy (Data are shown for children with parasites detected in a thick blood film). (a) Moderate-to-high transmission area. (b) Low transmission area.

associated with a dramatic improvement in the targeting of ACT treatments; 94.2% of children in the mRDT intervention arm received appropriately targeted treatment compared with 25.0% on the control arm (odds ratio 162.9, 95% CI 83.0–319.6; $P < 0.001$). The proportion of children who received appropriately targeted treatment within 24 h was also significantly higher in the intervention arm (72.1% *vs.* 6.0%, $P < 0.001$).

Discussion

This study confirms that use of mRDTs by CHWs can reduce the number of ACTs used, as documented in

previous studies [10, 14, 15], and additionally demonstrates that mRDTs can substantially improve the targeting of ACT treatment to children with malaria in community-based treatment programmes. With use of mRDT-based diagnosis, the proportion of children receiving appropriately targeted ACT treatment from CHWs (consistent with their true malaria infection status as determined by later expert microscopy) exceeded 80% in both transmission settings; a significant increase over presumptive treatment ($P < 0.001$ in both sites). The effect was more marked in the low transmission area where more than 90% of the patients received appropriately targeted treatment in the mRDT arm. This could be attributable to the combination of high specificity of mRDT in a setting of low and unstable malaria transmission, where nearly 100% of mRDT negatives were negative by light microscopy, and high adherence to mRDT results by CHWs. In contrast, where CHWs followed presumptive diagnosis, more than 90% of patients subsequently found to be slide negative had received an unnecessary ACT treatment. This concurs with previous reports that over-use of ACTs is likely to be higher in areas with low malaria prevalence [16, 17]. A high degree of adherence to test results by CHWs has frequently been observed in studies among CHWs, in contrast to the less favourable reports from research among health facility-based providers and some other community programmes [18–23]. Factors which may have contributed to high adherence in our trial were the comprehensive and participatory training that CHWs received, including clear guidance on referral criteria and how to handle RDT-negative patients, and community meetings to create awareness that not all fevers are due to malaria and explain the rationale for diagnostic testing at community level. Furthermore, the use of job aids, previously found to be an important aid for CHWs to interpret and adhere to mRDT results [23], and supportive supervision during the immediate post-training period, may have sustained the awareness and adherence to guidelines [24] and enhanced CHWs self-esteem and confidence in what they were doing. Educative interaction between caretakers and health workers has been shown to be a major factor for community acceptability of RDT use [25]. Close proximity of CHWs to other members of the community, coupled with community sensitisation and the communication training provided to CHWs as part of the intervention, may also have facilitated high adherence to mRDT results by CHWs.

More than 80% of patients with fever in the intervention and control arms in both transmission settings consulted CHWs for treatment within 24 h after onset of symptoms, which is much higher than has previously

been observed at health facilities in Uganda [11] and elsewhere [26]. These data show that CHWs provide an opportunity for improving the speed of treatment seeking for febrile illnesses in rural areas, where poor access to health facilities, lack of drugs, perceived high cost and unfriendly attitude of health workers often result in delayed treatment [27–32] and illustrate the role of community-based treatment programmes in increasing access to prompt effective treatment of malaria.

The sensitivity of mRDTs in this study was lower than has been previously observed among CHWs [23], particularly in the low malaria area, which could be due to the large proportion of low parasite density infections observed in those patients who were untreated, and which may therefore have been undetected by mRDT [33, 34]. Blood slides were prepared by CHWs, which was found to be a particular limitation in our study and others [14], and reduced the number of samples examined by microscopy and thus available for analysis, especially in the low transmission area. Nonetheless, the characteristics of patients included in the final analysis and CHWs were comparable between arms and we do not consider our findings could be attributed to selection bias. The mRDTs used passed independent quality-assurance batch testing, and we can confidently exclude test performance as a reason for low sensitivity. As the majority of false negatives were low-density infections, we can also exclude the possibility that this was due to a prozone effect; though the frequency of HRP-2 deletions in this population is unknown [35]. Other possible causes for false-negative mRDT results include operator error, especially where a CHW works under poor lighting conditions and/or at night [35]. Nonetheless, as missed treatment was frequently observed in low-density infection, below the acknowledged limit of detection of most mRDTs, we consider this to be the most likely cause for this observation. False positives were higher in the high transmission area than in the low transmission area, as would be expected due to persistent antigenaemia in individuals recently infected by malaria in hyperendemic areas [36].

The benefits of using mRDTs to improve targeting of ACTs and limit their overuse need to be weighed against the risks of not treating an infected child [37]. Among semi-immune children with low parasite counts in the moderate-to-high transmission area, the probability that the fever is attributable to malaria is low [38, 39], and antimalarial treatment is not necessarily required. However, missed treatment in non-immune subjects in the low transmission area is of greater potential concern. A limitation of this study was that we did not follow up patients to see if they recovered so we do not know the

clinical outcome in those who missed receiving treatment when they were mRDT negative but proved to be parasite-positive on microscopy. Poor sensitivity of HRP-2-based mRDTs has previously been reported from other areas of low transmission [33, 34], and more sensitive point-of-care diagnostic techniques, of low cost and suitable for routine use in these low transmission settings, are needed. Thus, before scaling up mRDT use by CHWs in low transmission areas, we would suggest that safety studies with follow-up data on patients who missed treatment due to low sensitivity of current mRDTs be conducted to adequately assess the risk of non-treatment of low-density infections in non-immunes. It is conceivable that missed treatments are more frequent in community-based programmes than in other health services using mRDTs, as patients may be more likely to seek care at an earlier stage in their illness. Parasite density among patients presenting to CHWs may therefore be lower than in patients who first present to health facilities, and a greater proportion of them may have an infection below the detection threshold of current mRDTs, irrespective of local transmission intensity. Encouraging patients with no symptoms other than fever, who test mRDT negative, to return to the CHW for re-evaluation and retesting whether symptoms do not improve, could help mitigate the risk of not treating an infected child.

Conclusion

The findings presented here underscore the value of mRDT-based diagnosis of malaria in reducing overuse of ACTs in community case management and should be of particular interest to malaria programme managers and policymakers, nationally, regionally and internationally as countries scale up iCCM [40]. Equipping CHWs with mRDTs markedly improved the appropriate targeting of ACT treatment. With increased financing for malaria and large-scale control, the prevalence of malaria should reduce and the potential role of mRDTs in targeting malaria treatment and disease surveillance will become ever more critical [41] at all levels of health service delivery, including community level. Use of mRDTs and diagnostic algorithms has the additional potential to also improve detection and treatment of non-malaria fevers. Our data show mRDT use was beneficial in improving the targeting of ACT use in both moderate-to-high and low transmission areas and that a widespread adoption of mRDTs at community level can reduce misdiagnosis and inappropriate treatment of febrile illness in all malaria transmission settings. Nonetheless, mRDTs have several limitations that may reduce their utility in low transmission settings because they do not reliably detect

low-density parasitaemia. Studies have shown that in infants, parasitaemia is synonymous to clinical malaria [42]. Therefore, missed treatments due to the low sensitivity of current mRDTs to low-density infections (as reported here and in other areas of low transmission [34]) are a concern and suggest that despite the potential cost savings from reduced use of ACTs, presumptive diagnosis and treatment of all fevers as malaria may remain advisable in malarious areas where populations have little or no immunity, until such time as more sensitive diagnostic assays become widely available.

Acknowledgements

The authors wish to acknowledge the participation of CHWs who treated children that consulted them with fever during the study period; the valuable contribution of the laboratory technicians who performed the microscopy (Dickson Birakwate, Phiona Kafuko, Betty Nabatte, Anna Mary Auma and Annet Enzaru); Clare Chandler who helped develop the intervention, Carolyn Lynch who helped develop the training materials and Bonnie Cundill for statistical advice. This work was supported by the ACT Consortium, funded through a grant from the Bill and Melinda Gates Foundation to the London School of Hygiene and Tropical Medicine. Sian Clarke was supported by the Wellcome Trust through a Research Career Development Fellowship (084933).

References

- World Health Organisation. Implementation of the Global malaria control strategy. Report of a WHO study group on the implementation of the global plan of action for malaria control 1993–2000. *World Health Organ Tech Rep Ser* 1993; 839: 1–57.
- World Health Organisation. *Guidelines for the Treatment of Malaria*, 2nd edn. WHO: Geneva, 2010. <http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html>
- Marsh DR, Hamer DH, Pagnoni F, Peterson S. Introduction to a special supplement: evidence for implementation, effects, and impact of integrated community case management strategy to treat childhood infection. *Am J Trop Med Hyg* 2011; 87(Suppl. 5): 2–5.
- D'Acremont V, Lengeler C, Mshinda H, Mtasiwa D, Tanner M, Genton B. Time to move from presumptive malaria treatment to laboratory-confirmed diagnosis and treatment in African children with fever. *PLoS Med* 2009; 6: e252.
- Harvey SA, Jennings L, Chinyama M, Masaninga F, Mulholland K, Bell DR. Improving community health worker use of malaria rapid diagnostic tests in Zambia: package instructions, job aid and aid-plus-training. *Malaria J* 2008; 7: 160.
- Ukwaja KN, Ainna OB, Talabi AA. Clinical overlap between malaria and pneumonia: can malaria rapid diagnostic test play a role? *J Infect Dev Count* 2011; 5: 199–203.
- World Health Organization. *Universal Access to Malaria Diagnostic Testing. An Operational Manual*. WHO: Geneva, 2011.
- Chandramohan D, Carneiro I, Kavishwar A *et al.* A clinical algorithm for the diagnosis of malaria: results of an evaluation in an area of low endemicity. *Tropical Med Int Health* 2001; 6: 505–510.
- Lemma H, Byass P, Desta A *et al.* Deploying artemether-lumefantrine with rapid testing in Ethiopian communities: impact on malaria morbidity, mortality and healthcare resources. *Tropical Med Int Health* 2010; 15: 241–250.
- Yeboah-Antwi K, Piligana P, Macloed WB *et al.* Community case management of fever due to malaria and pneumonia in children under five in Zambia: a cluster randomized controlled trial. *PLoS Med* 2010; 7: e1000340.
- Uganda Bureau of Statistics (UBOS) and ICF Macro. *Uganda Malaria Indicator Survey 2009*. UBOS and ICF Macro: Calverton, Maryland, USA, 2010.
- USAID Quality Assurance Project and World Health Organization. *How to Use a Rapid Diagnostic Test (RDT): A Guide for Training at a Village and Clinic Level (Modified for Training in the Use of the Generic Pf Test for Falciparum Malaria)*. WHO: Bethesda, MD, and Geneva, 2008.
- Hayes R, Moulton L. *Cluster randomised trials*. CRC Press: London, 2009.
- Mubi M, Janson A, Warsame M *et al.* Malaria rapid testing by community health workers is effective and safe for targeting malaria treatment: randomised cross-over trial in Tanzania. *PLoS ONE* 2011; 6: e19753.
- Rutta ASM, Francis F, Mmbando BP *et al.* Using community-owned resource persons to provide early diagnosis and treatment and estimate malaria burden at community level in north-eastern Tanzania. *Malaria J* 2012; 11: 152.
- Lubell Y, Reyburn H, Mbakilwa H *et al.* The impact of response to the results of diagnostic tests for malaria: cost-benefit analysis. *BMJ* 2008; 336: 202–205.
- Shillcutt S, Morel C, Goodman C *et al.* Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. *Bull World Health Org* 2009; 86: 101–110.
- Chinkumba J, Skarbinski J, Chilima B *et al.* Comparative field performance and adherence to test results of four malaria rapid diagnostic tests among febrile patients more than five year of age in Blantyre, Malawi. *Malaria J* 2010; 9: 209.
- Mukanga D, Babirye R, Peterson S *et al.* Can lay community workers be trained to use diagnostics to distinguish and treat malaria and pneumonia in children? Lessons from rural Uganda. *Tropical Med Int Health* 2011; 16: 1234–1242.
- Uzochukwu BSC, Onwujekwe E, Ezuma NN, Ezeoke OP, Ajuba MO, Sibeudu FT. Improving rational treatment of

R. Ndyomugenyi *et al.* **ACT use by community health workers based on RDTs**

- malaria: perceptions and influence of RDTs on prescribing behaviour of health workers in Southeast Nigeria. *PLoS ONE* 2011; **6**: e14627.
21. Kabaghe AN, Visser BJ, Spijker R, Phiri KS, Grobusch MP, van Vugt M. Health workers' compliance to rapid diagnostic tests (RDTs) to guide malaria treatment: a systematic review and meta-analysis. *Malaria J* 2016; **15**: 163.
 22. Mukanga D, Tiono AB, Anyorigiya T *et al.* Integrated community case management of fever in children under five using rapid diagnostic tests and respiratory rate counting: a multi-country cluster randomized trial. *Am J Trop Med Hyg* 2012; **87**: 21–29.
 23. Ruizendaal E, Dierickx S, Grietens KP, Schallig HDFH, Pagnoni F, Mens PF. Success or failure of critical steps in community case management of malaria with rapid diagnostic tests: a systematic review. *Malaria J* 2014; **13**: 229.
 24. Staedke SG, Mwebaza N, Kamya MR *et al.* Home management of malaria with artemether-lumefantrine compared with standard care in urban Ugandan children: a randomized controlled trial. *Lancet* 2009; **373**: 1623–1631.
 25. Baiden F, Owusu-Agyenyi S, Okyere E *et al.* Acceptability of rapid diagnostic test-based management of Malaria among caregivers of under-five children in rural Ghana. *PLoS ONE* 2012; **9**: e45556.
 26. Gitonga CW, Amin AA, Ajanga A, Kangwana BB, Noor AM, Snow RW. The use of artemether-lumefantrine by febrile children following national implementation of a revised drug policy in Kenya. *Tropical Med Int Health* 2008; **13**: 487–494.
 27. D'Ambruoso L, Abbey M, Hussein J. "Please understand when I cry out in pain": women's accounts of maternity services during labour and delivery in Ghana. *BMC Public Health* 2005; **5**: 140.
 28. Deressa W, Ali A. Malaria-related perceptions and practices of women with children under the age of five years in rural Ethiopia. *BMC Public Health* 2009; **9**: 259.
 29. Kiwanuka SN, Ekirapa EK, Peterson S *et al.* Access to and utilisation of health services for the poor in Uganda: a systematic review of available evidence. *Trans R Soc Trop Med Hyg* 2008; **102**: 1067–1074.
 30. Kpanake L, Dassa KS, Muller E. Why most Tongolese people do not seek care for malaria in health care facilities: a theory-driven inventory of reasons. *Psychol Health Med* 2009; **14**: 502–510.
 31. Ndyomugenyi R, Neema S, Magnussen P. The use of formal and informal services for antenatal care and malaria treatment in rural Uganda. *Health Policy Plan* 1998; **13**: 94–102.
 32. Rutebemberwa E, Nsabagasani X, Pariyo G, Tomson G, Peterson S, Kallander K. Use of drugs, perceived drug efficacy and preferred providers for febrile children: implications for home management of fever. *Malaria J* 2005; **8**: 31.
 33. McMorro ML, Aidoo M, Kachur P. Malaria rapid diagnostic tests in elimination settings-can they find the last parasite? *Clin Microbiol Inf* 2011; **17**: 1624–1631.
 34. Shakely D, Elfving K, Aydin-Schmidt B *et al.* The usefulness of rapid diagnostic tests in the new context of low malaria transmission in Zanzibar. *PLoS ONE* 2013; **8**: e72912.
 35. Maltha J, Gillet P, Jacobs J. Review: malaria rapid diagnostic tests in endemic settings. *Clin Microbiol Infect* 2013; **19**: 399–407.
 36. Kyababainze DJ, Tibenderana JK, Odong GW, Rwakimari JB, Counihan H. Operational accuracy and comparative persistent antigenicity of HRP2 rapid diagnostic tests for *Plasmodium falciparum* malaria in a hyperendemic region of Uganda. *Malaria J* 2008; **29**: 221.
 37. Björkman A, Mårtensson A. Risks and benefits of targeted malaria treatment based on rapid diagnostic test results. *Clin Infect Dis* 2010; **51**: 512–514.
 38. Armstrong-Schellenberg JRM, Smith T, Alonso PL, Hayes RJ. What is clinical malaria? Finding case definitions for field research in highly endemic areas. *Parasitology Today* 1994; **10**: 439–442.
 39. Bolond PB, Boriga DA, Ruebush YK *et al.* Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission II. Descriptive epidemiology of malaria infection and disease among children. *Am J Trop Med Hyg* 1999; **60**: 641–648.
 40. Young M, Walfheim C, Marsh DR, Hammamy D. World Health Organization/United Nations Children's Fund Joint Statement on Integrated Community Case Management: An Equity Focussed Strategy to Improve Access to Essential Treatment Services for Children. *Am J Trop Med Hyg* 2012; **87**(Suppl. 5): 6–10.
 41. Perkins M, Bell D. Working without a blindfold: the critical role of diagnosis is essential to achieving long term goals. *Malaria J* 2008; **7** (Suppl 1): S5.
 42. McGuinness D, Koram K, Bennett S, Wagner G, Nkrumah F, Riley E. Clinical case definition for malaria: clinical malaria associated with very low parasite densities in African children. *Trans R Soc Trop Med Hyg* 1998; **92**: 527–531.

Corresponding Author Siân E. Clarke, Department of Disease Control, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. E-mail: Sian.Clarke@lshtm.ac.uk